Home › NCT06798298
A Safety and Efficacy Long-Term Follow-up Study of Adult Participants Treated With Gene Modified T Cells
A Long-Term Follow-up Protocol for Participants Treated With Gene Modified T Cells
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: 1. All participants who received at least one GM T cell infusion in a previous 2seventy bio (prior to April 2024) or Regeneron Pharmaceuticals sponsored study, and have completed the post-treatment follow-up period on the parent treatment protocol, or discontinued follow-up on the parent protocol after completing at least 6 months of safety monitoring, as applicable. 2. Participant (and legal representative, when applicable) must understand and voluntarily sign an Informed Consent Form (ICF)/Informed Assent Form (IAF) prior to any study related assessments/procedures being conducted. Exclusion Criteria: Not applicable.
About the study
This is a prospective study for the Long-Term Follow-Up (LTFU) of safety and efficacy of all participants exposed to gene modified (GM) T cell therapy in accordance with Health Authorities' guidance for participants treated with gene therapy products.
Participants who received at least one infusion of gene modified T cells in a 2seventy bio (prior to April 2024) or Regeneron Pharmaceuticals sponsored study will be asked to participate in this LTFU protocol, upon either premature discontinuation from, or completion of the parent treatment protocol.
Participants enrolled in this LTFU protocol will have safety assessments, laboratory evaluations, and complete patient-reported outcome (PRO) questionnaires at scheduled intervals as applicable.
What is being tested
- Non-interventional (genetic)
Sponsor: Regeneron Pharmaceuticals · Participants: 50 · Started: Nov 10, 2025
Contact the study team
- Clinical Trials Administrator · Phone: 844-734-6643
Official record on ClinicalTrials.gov — NCT06798298
Locations in the U.S.
| Tennessee | Tennessee Oncology, Nashville |
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.